GlassScriptPhysician profile
Patricia A Hoffmann
NPI 1528197803
$3,379.53
in general payments reported to CMS, 2019-2025
20 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $500 · 2023: $1,002 · 2024: $588 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Education: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.67 |
| Education | $518.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $724.31 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $484.89 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $298.90 | 2021-2025 | |
| Janssen Biotech, INC. | $273.62 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $252.70 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $216.08 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Incyte Corporation | $180.56 | 2022-2025 | Opzelura |
| Ucb, INC. | $156.40 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $142.92 | 2022-2024 | Libtayo, Dupixent |
| Leo Pharma INC. | $134.89 | 2025 | Anzupgo, Adbry |
| Pfizer INC. | $134.17 | 2022-2025 | |
| Amgen INC. | $117.24 | 2022-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Genzyme Corporation | $47.67 | 2022-2024 | |
| Arcutis Biotherapeutics, INC. | $27.44 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $23.84 | 2025 | Hyrimoz |
| Surgenex LLC | $20.32 | 2025 | Surgraft, Ardeograft, Pellograft |
| Biofrontera INC. | $19.94 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.73 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.